- Login
- Manage Portfolio
- Post a StockTalk
- Write an Instablog
- Get Daily Email Alert
-
Seeking Alpha
|
|
| 52wk high: | |
| 52wk low: | |
| EPS: | |
| PE: | |
| Dividend: | |
| Yield: | |
| Market Cap: | |
| Exchange: | |
Articles on Watson Pharmaceuticals Inc. (WPI)
by latest | most commented
-
Winners and Losers Since the 6/12 Market High
-
Healthcare: Branded Pharma Out, Diagnostics / Generics In
-
Watson Pharmaceuticals Says to Look Ahead to June 2009 Earnings
-
Expect FDA Approval of AMAG Pharmaceutical's Feraheme
-
Pharma Announces $80B Reduction: Who Wins?
-
A Healthy Dose of Funding for Pharma, Biotech
-
FDA Calendar Updates: Trinity Biotech Awaiting Two Responses
-
Health Care Trends Part 2: M&A, Generic Competition, CROs
-
27 Earnings Season Growth Leaders
-
Wall Street Breakfast: Must-Know News
-
FDA, Clinical Trial Updates: Watson Pharma, United Therapeutics, Auxilium, Dendreon
-
FDA, Clinical Trial Calendar Updates: Genzyme, Isis, Osiris, Roche, Watson
-
Tuesday Options Update: COH, WPI, HAL, XLB, ORCL & XLY
-
Impax Labs: Strong Balance Sheet, Focused R&D
-
Biotech Dip: Sector Weakness, or Buying Opportunity?
-
Momenta Pharma Pursuing a Three-Part Strategy
-
Biotech Going Generic Like Big Pharma?
-
Best and Worst Performing S&P 500 Stocks Since 2/12
-
12 S&P 500 Stocks with Bullish Character in a Bearish Realm
-
Wall Street Breakfast: Must-Know News
-
Updated Clinical Trial and FDA Calendars
-
Six Sectors Presenting Opportunities as Obama Takes Office
-
Hedge Fund Portfolio Tracking: SAC Capital (Steven Cohen), Q3 2008
-
Watson Pharmaceuticals: A Potent Drug Combination
-
New Index of Health Product Innovators
-
Generic Drug Price War Ramps Up
-
Strong Dollar's Impact on Pharma vs. Generics
-
Stocks Offering 'Healthy' Returns
-
Bullish Outlook for Generic Drugs Post-Election
-
Wall Street Breakfast: Must-Know News
-
Huge Opportunity - Fast Money Midday (8/14/08)
-
Thursday Options Outlook: WPI, ADSK, DNA, NITE, LEN, CTRP, FRX, IDCC
-
Wednesday Options Outlook: KRE, STI, WPI, IYR, BGG, SWY
-
31 S&P 500 Stocks with Negative 3 FY Net Income
-
Watson Pharmaceuticals: The World According to GARP
-
Watson Pharmaceuticals Turning Things Around
-
Biotechs Make Appearances in Best and Worst Lists of WSJ Review
-
Watson Pharmaceuticals and GlaxoSmithKline Settle Patent Suit
-
Generic vs. Generic: Teva, for Example
-
Biotech Stocks Day-in-Review: BioCryst Begins Pivotal Trial of Fodosine
-
Watson Pharmaceuticals: Don't See The Miracle Cure